First Quarter Financial Report

15. May 2018 | 2 min read

Moss, 15 May 2018
Gentian Diagnostics AS announces its results for the first quarter of 2018. The highlights include
  • Record level for total operating revenue of MNOK 11.2 for the quarter
  • 100 % growth in sales revenue compared to 1Q17
  • 24 % growth in sales revenue compared to 4Q17
  • Strong sales for both Cystatin C and fCal
  • New Proof-of-Concept announced post end of quarter

Please find the report enclosed. The report will also be made available on www.gentian.com.

 
For further information, please contact:
Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
 
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
 
 
MeldingsID:  451378
 
 

You may also read


Feb 12, 2026 - Ole Sørlie

Gentian Diagnostics: Key information relating to the proposed cash dividend

Moss, 12 February 2026 The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per..

Read more

Feb 11, 2026 - Ole Sørlie

Update on the development of the NT-proBNP assay

Gentian Diagnostics ASA announces an update on the development of its NT proBNP assay. Recent investigations..

Read more

Feb 11, 2026 - Ole Sørlie

Gentian Diagnostics: Fourth quarter 2025 report

Moss, 11 February 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic..

Read more